White Paper

Excellence In Immuno-Oncology Clinical Trials

By Erin Finot, MS, MBA, Vice President, Immuno-Oncology & Cell And Gene Therapy

GettyImages-1460874812 cancer patient

Over the past ten years, the introduction of immuno-oncology (IO) therapies has brought about a revolutionary change in the treatment of cancer patients worldwide. Biotechnology has also played a crucial role in driving translational science, developing therapeutic platforms, and designing new trials to support the progress of IO treatments. Nevertheless, biotech sponsors venturing into clinical studies for IO therapies must be ready to confront distinctive scientific and operational obstacles.

This white paper reviews IO innovation in cell and gene therapies, as well as five primary operational challenges, including diversity in patient enrollment, and how to plan for success.

access the White Paper!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader